A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma.
about
Transformation of SV40-immortalized human uroepithelial cells by 3-methylcholanthrene increases IFN- and Large T Antigen-induced transcripts.Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule.IL-18 inhibits growth of murine orthotopic prostate carcinomas via both adaptive and innate immune mechanismsDevelopment of viral vectors for gene therapy for chronic painAdenovirus as vehicle for anticancer genetic immunotherapy.Recent clinical progress in virus-based therapies for cancer.Trial watch: DNA vaccines for cancer therapy.Targeted delivery of murine IFN-gamma using a recombinant fowlpox virus: NK cell recruitment to regional lymph nodes and priming of tumor-specific host immunity.A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality.Adenoviral vector-based strategies for cancer therapy.Adenovirus-mediated delivery of the human IFN-γ gene potentiates the cytotoxicity of daunorubicin against leukemic cells through downregulation of the α4β1 integrin/ILK/apoptosis pathway.Intratumoral immunotherapy for melanoma.Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing interferon-γ) in metastatic melanoma patients.Trial Watch: DNA vaccines for cancer therapy.Re-inventing intratumoral immunotherapy for melanoma.Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK).Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion.
P2860
Q33763538-E7A8D5F5-4FBC-4C28-8EC5-0AD17DB90AB9Q33965681-5806AFD5-1F59-40F1-865A-9879DA76DD66Q34026026-0E740180-D4C2-4508-A493-6B06400F3E5CQ35430864-216D2620-EDFF-473C-A771-EDE051F3DEBEQ36288930-AF11DAFF-3264-4608-B4FD-45C8C8E8B49FQ36627242-3E2AB394-C23C-4C99-9CA8-BCBE68D93720Q36845824-8721B789-0CE3-4E69-9AAA-D9B915AF37F6Q36868877-D58BEA03-9E91-45F9-BAE2-9B4A5D567B18Q37091111-FA336F13-AF84-4B73-99CA-2E73A2FB58CAQ37409025-FE37612C-3779-4BF5-B0F9-80561153E6FEQ37438021-8580B496-07F6-428D-946E-3CA072AACE22Q38518518-F66E0423-2DAE-4B33-8708-958C9CB119C0Q38890435-4D450D8C-49DD-4E4C-87EC-8057D84ABD48Q42552005-F08444D3-EE5F-4B44-BDE4-402289B3CF04Q44607083-2F18CFAE-94CE-4808-80C4-1D067D67A8A5Q46085597-841F8F4A-4EF6-437B-94E1-266E9F85D79DQ55015760-DEDBDF0C-32BE-4188-AC9B-043F502A3F18
P2860
A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
A phase I trial of immunothera ...... ients with malignant melanoma.
@en
type
label
A phase I trial of immunothera ...... ients with malignant melanoma.
@en
prefLabel
A phase I trial of immunothera ...... ients with malignant melanoma.
@en
P2093
P2860
P921
P356
P1433
P1476
A phase I trial of immunothera ...... tients with malignant melanoma
@en
P2093
D M Sahasrabudhe
J D Rosenblatt
M Ladrigan
P2860
P2888
P304
P356
10.1038/SJ.CGT.7700568
P577
2003-04-01T00:00:00Z
P5875
P6179
1003110134